It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purpose
Several recent articles discuss the need for a definition of chronic kidney disease (CKD) that embarks age-dependency and its impact on the prevalence of CKD. The relevance is derived from the common knowledge that renal function declines with age. The aim of this study was to calculate age-dependent eGFR lower reference limits and to consider their impact on the prevalence of CKD.
Methods
A real-world data set from patients with inconspicuous urinalysis was used to establish two quantile regression models which were used to calculate continuous age-dependent lower reference limits of CKD–EPI, FAS and EKFC–eGFR based on either single eGFR determinations or eGFR values that are stable over a period of at least 3 months (± 10% eGFR). The derived lower reference limits were used to calculate the prevalence of CKD in a validation data set. Prevalence calculation was done once without and once with application of the chronicity criterion.
Results
Both models yielded age-dependent lower reference limits of eGFR that are comparable to previously published data. The model using patients with stable eGFR resulted in higher eGFR reference limits. By applying the chronicity criterion, a lower prevalence of CKD was calculated when compared to one-time eGFR measurements (CKD–EPI: 9.8% vs. 8.3%, FAS: 8.0% vs. 7.2%, EKFC: 9.0% vs. 7.1%).
Conclusion
The application of age-dependent lower reference intervals of eGFR together with the chronicity criterion result in a lower prevalence of CKD which supports the estimates of recently published work and the idea of introducing age-dependency into the definition of CKD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Infectious Diseases and Genetics “Prof. Schenk/Dr. Ansorge & Colleagues”, Medical Laboratory for Clinical Chemistry, Microbiology, Magdeburg, Germany; Otto-Von-Guericke-University Magdeburg, Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, Magdeburg, Germany (GRID:grid.5807.a) (ISNI:0000 0001 1018 4307)
2 Infectious Diseases and Genetics “Prof. Schenk/Dr. Ansorge & Colleagues”, Medical Laboratory for Clinical Chemistry, Microbiology, Magdeburg, Germany (GRID:grid.5807.a)
3 Otto-Von-Guericke-University Magdeburg, Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, Magdeburg, Germany (GRID:grid.5807.a) (ISNI:0000 0001 1018 4307)